Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Exploring patient and clinician perspectives for homologous recombination deficient (HRD) biomarker testing to guide precision medicine for advanced ovarian cancer treatment: A qualitative study. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Unresolved reference
External reference
High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints
10.3390/ijms20040952 · 2019 · External reference
PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance
10.3389/fcell.2020.564601 · 2020 · External reference
Homologous recombination deficiency: concepts, definitions, and assays
10.1093/oncolo/oyab053 · 2022 · External reference
Prevalence of homologous recombination deficiency in first-line PARP inhibitor maintenance clinical trials and further implication of personalized treatment in ovarian cancer
10.3390/cancers15123095 · 2023 · External reference
BRCA mutation in high grade epithelial ovarian cancers
10.1016/j.gore.2019.07.007 · 2019 · External reference
Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer
10.1056/nejmoa1810858 · 2018 · External reference
The poly (ADP ribose) polymerase inhibitor niraparib: management of toxicities
10.1016/j.ygyno.2018.01.011 · 2018 · External reference
Unresolved reference
External reference
Shared decision-making as a method of care
10.1136/bmjebm-2022-112068 · 2023 · External reference
Recombination deficiency testing to inform patient decisions about Niraparib maintenance therapy for high-grade serous or endometrioid epithelial ovarian cancer: a health technology assessment
2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Applying the health belief model to explore healthcare provider and patient perspectives on homologous recombination deficiency testing in cancer: a narrative review
2026 · External reference
Unresolved reference
External reference
10.1093/intqhc/mzm042
10.1093/intqhc/mzm042 · External reference
10.1177/02692163241234800
10.1177/02692163241234800 · External reference
How do you solve a problem like COREQ? A critique of Tong et al.’s (2007) consolidated criteria for reporting qualitative research
10.1016/j.metip.2024.100155 · 2024 · External reference
Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support
10.1016/j.jbi.2008.08.010 · 2009 · External reference
Qualitative research: standards, challenges, and guidelines
10.1016/s0140-6736(01)05627-6 · 2001 · External reference
Unresolved reference
External reference
Reflecting on reflexive thematic analysis
10.1080/2159676x.2019.1628806 · 2019 · External reference
Using thematic analysis in psychology
10.1191/1478088706qp063oa · 2006 · External reference
Refining PARP inhibitor use in HGSOC: The role of HRD testing in clinical decision making
10.1016/j.ygyno.2026.01.215 · 2026 · External reference
Implementing HRD testing in routine clinical practice on patients with primary high-grade advanced ovarian cancer
10.3390/cancers15030818 · 2023 · External reference
Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success
10.1080/14796694.2024.2433412 · 2025 · External reference
Understanding communication between patients and healthcare professionals regarding comprehensive biomarker testing in precision oncology: a scoping review
10.1002/cam4.6913 · 2024 · External reference
Exploring cancer patients’ and caregivers’ perspectives and knowledge regarding biomarker testing in Canada
10.3390/curroncol32060292 · 2025 · External reference
Unresolved reference
External reference
I think that a brief conversation from their provider can go a very long way”: patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer
2021 · External reference
What you’re hearing from all of us is simplify the language”: patient perspectives on biomarker testing in ovarian cancer
10.1016/j.ygyno.2025.08.009 · 2025 · External reference
The Development and testing of a patient decision aid for individuals with homologous recombinant proficient ovarian cancer who are considering Niraparib maintenance therapy
10.3390/curroncol31030107 · 2024 · External reference
10.1016/j.ygyno.2024.07.585
10.1016/j.ygyno.2024.07.585 · External reference
Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: a qualitative study
10.1016/j.ygyno.2020.10.034 · 2021 · External reference
A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer
10.1016/j.ygyno.2017.05.039 · 2017 · External reference
Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment
10.1016/j.ygyno.2020.01.026 · 2020 · External reference
Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: findings from two online community events
2022 · External reference
Reinforcing the humanity in healthcare: the Glasgow Consensus Statement on effective communication in clinical encounters
10.1016/j.pec.2024.108158 · 2024 · External reference
